AU2021264554A1 - Compounds and methods for prevention and treatment of coronavirus infections - Google Patents

Compounds and methods for prevention and treatment of coronavirus infections Download PDF

Info

Publication number
AU2021264554A1
AU2021264554A1 AU2021264554A AU2021264554A AU2021264554A1 AU 2021264554 A1 AU2021264554 A1 AU 2021264554A1 AU 2021264554 A AU2021264554 A AU 2021264554A AU 2021264554 A AU2021264554 A AU 2021264554A AU 2021264554 A1 AU2021264554 A1 AU 2021264554A1
Authority
AU
Australia
Prior art keywords
cov
themethodofclaim
thecomposition
sars
whereinthecoronavirusissars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021264554A
Other languages
English (en)
Inventor
Hao Chiang
Wei-Chung CHIOU
Cheng Huang
Hui-Ju Liang
Pei-Hsin Lin
Jir-Mehng Lo
Yeh B. WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arjil Biotech Holding Co Ltd
Original Assignee
Arjil Biotech Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arjil Biotech Holding Co Ltd filed Critical Arjil Biotech Holding Co Ltd
Publication of AU2021264554A1 publication Critical patent/AU2021264554A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021264554A 2020-05-01 2021-04-29 Compounds and methods for prevention and treatment of coronavirus infections Pending AU2021264554A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018690P 2020-05-01 2020-05-01
US63/018,690 2020-05-01
PCT/US2021/029840 WO2021222534A1 (en) 2020-05-01 2021-04-29 Compounds and methods for prevention and treatment of coronavirus infections

Publications (1)

Publication Number Publication Date
AU2021264554A1 true AU2021264554A1 (en) 2023-01-05

Family

ID=78292168

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021264554A Pending AU2021264554A1 (en) 2020-05-01 2021-04-29 Compounds and methods for prevention and treatment of coronavirus infections

Country Status (7)

Country Link
US (1) US12433901B2 (https=)
EP (1) EP4142713A1 (https=)
JP (1) JP7805010B2 (https=)
CN (1) CN116568295B (https=)
AU (1) AU2021264554A1 (https=)
TW (1) TW202206080A (https=)
WO (1) WO2021222534A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023535714A (ja) * 2020-07-23 2023-08-21 アージル・バイオテック・ホールディング・カンパニー・リミテッド ウイルス感染を阻害するための方法および組成物
US20240408055A1 (en) * 2021-10-21 2024-12-12 Peking University Shenzhen Graduate School Use of anisomelic acid in preparation of pharmaceutical composition for inhibiting infection and replication of sars-cov-2 and variants

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140105928A1 (en) * 2004-01-06 2014-04-17 Paul Edward Stamets Antiviral and antibacterial activity from medicinal mushrooms
CA2481489A1 (en) * 2002-11-29 2004-06-17 Morinaga Milk Industry Co., Ltd. Cysteine protease inhibitor
TWI389699B (zh) * 2009-02-13 2013-03-21 高雄醫學大學 用於誘導細胞凋亡之樟芝子實體乙醇萃取物及其製備方法
US7919665B2 (en) 2009-02-17 2011-04-05 Conocophillips Company Mercury removal from hydrocarbons
TW201231474A (en) * 2011-01-26 2012-08-01 Univ Kaohsiung Medical Triterpenoid composition of Antrodia cinnamomea, preparation and analysis method thereof
FI126047B (en) * 2012-08-28 2016-06-15 John Eriksson Pharmaceutical compositions of anisomelic acid and their use
TWI453026B (zh) * 2013-05-14 2014-09-21 Jenisa Biotechnology Corp Ltd 魚針草萃取物及其純化物抗流感病毒之用途
US9645651B2 (en) 2013-09-24 2017-05-09 Microsoft Technology Licensing, Llc Presentation of a control interface on a touch-enabled device based on a motion or absence thereof
US11253527B2 (en) * 2019-02-25 2022-02-22 Arjil Biotech Holding Company Limited Method and composition for inhibiting virus infection
WO2021202982A1 (en) * 2020-04-03 2021-10-07 Turtle Bear Holdings, Llc Compositions and methods for modulating inflammatory response
CN113521060B (zh) * 2020-04-17 2022-12-06 北京大学深圳研究生院 鱼针草内酯抗新型冠状病毒的用途
TW202200175A (zh) * 2020-04-28 2022-01-01 浩峰生物科技股份有限公司 牛樟芝萃取物(Ant-Ex)減少血管收縮素轉換酶2(ACE-2)蛋白質表現

Also Published As

Publication number Publication date
JP7805010B2 (ja) 2026-01-23
EP4142713A1 (en) 2023-03-08
US12433901B2 (en) 2025-10-07
WO2021222534A1 (en) 2021-11-04
US20210338690A1 (en) 2021-11-04
JP2023524274A (ja) 2023-06-09
TW202206080A (zh) 2022-02-16
CN116568295A (zh) 2023-08-08
CN116568295B (zh) 2026-02-13

Similar Documents

Publication Publication Date Title
US20230148179A1 (en) SMALL MOLECULE INHIBITORS OF SARS-CoV-2 VIRAL REPLICATION AND USES THEREOF
AU2021264554A1 (en) Compounds and methods for prevention and treatment of coronavirus infections
Wang et al. Orally administered bismuth drug together with N-acetyl cysteine as a broad-spectrum anti-coronavirus cocktail therapy
Ahidjo et al. Current perspective of antiviral strategies against COVID-19
RU2382783C2 (ru) Органические соединения
JP2023515227A (ja) 抗コロナウイルスにおけるジスルフィラムの使用
JP7584161B2 (ja) Ｎ－置換ピリジルベンズイソセラゾロン化合物の使用
US20210379058A1 (en) Arylamide Compounds For Treatment And Prevention Of Viral Infections
EP4153158A1 (en) Use of psychotropic drugs for the treatment of coronavirus infections
US11963955B2 (en) Compositions for and methods of inhibiting SARS-CoV2 infection
WO2021196666A1 (zh) 高三尖杉酯碱在制备人体β-冠状病毒复制抑制剂中的应用
RU2010147881A (ru) ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА
BRPI0413585A (pt) composto ou sal farmaceuticamente aceitável ou um precursor hidrolisável in vivo deste, uso de um composto ou um sal deste farmaceuticamente aceitável, métodos para o tratamento de cáncer, e de infecções associadas com cáncer, composição farmacêutica, e, processo para preparação e uso de um composto ou um sal farmacêuticamente aceitável ou um precursor hidrolisável in vivo
Wang et al. SARS-CoV-2: Structure
US20240158368A1 (en) Pyrrolidine Main Protease Inhibitors as Antiviral Agents
TW202144380A (zh) 用於治療冠狀病毒感染之化合物
CN114504575A (zh) 泮托拉唑在制备抑制冠状病毒的产品及抗冠状病毒感染药物中的应用
CN119174746B (zh) 二苯甲酰甲烷用于抑制冠状病毒及治疗由其引起的相关疾病的用途
Önerci et al. Submandibular hydatid cyst: a case report
US20230002774A1 (en) Methods and compostions for inhibiting coronaviral replication
TWI917417B (zh) 治療病毒感染之方法及組合物
Zhu et al. The Tetrahydroisoquinoline Derivative SP9 Exhibits Antiviral Activity Against PEDV and MHV
UA18023U (en) Method for sclerotherapy of ovarian cysts
Gupta et al. A comprehensive review on cervical cancer; HPV infection to Prevention
US11045519B2 (en) Arginine-rich polypeptide compositions and methods of using same